Showing 531-540 of 23005 results for "".
Aligning PAH Treatment Plans With Key Care Goals and Your Patients’ Priorities
https://reachmd.com/programs/cme/aligning-pah-treatment-plans-with-key-care-goals-and-your-patients-priorities/33238/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.How Do Patient Experiences and PAH Perspectives Vary Across Regions and Cultures Worldwide?
https://reachmd.com/programs/cme/how-do-patient-experiences-and-pah-perspectives-vary-across-regions-and-cultures-worldwide/33245/Learn about applying patient-centered approaches in the management of pulmonary arterial hypertension (PAH) to optimize patient outcomes.Automated External Defibrillators at Home?
https://reachmd.com/programs/clinicians-roundtable/automated-external-defibrillators-at-home/3154/In recent years, we've seen automated external defibrillators (AED) distributed in high-traffic areas throughout many of our communities. Though more cases of sudden cardiac events are occurring outside the home-owing to greater mobility for our older, at-risk patients-a great many cases do still ocCommunity Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
https://reachmd.com/programs/cme/Community-Clinic-Translating-Data-Into-Action-Practical-Strategies-for-Optimizing-First-Line-RCC-Management/35774/Learn to apply evidence-based strategies to guide first-line therapy selection and manage treatment-related adverse events in advanced renal cell carcinomaCases From the Real World: 72-Year-Old Woman With CRVO
https://reachmd.com/programs/cme/Cases-From-the-Real-World-72-Year-Old-Woman-With-CRVO/33171/Hear how Drs. Ferhina Ali and Yasha Modi navigate the balance of extending treatment intervals while reducing the risk of recurrent ME in RVO.Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
https://reachmd.com/programs/cme/hitting-the-target-in-atopic-dermatitis-interdisciplinary-team-training-for-leveraging-il-13-inhibitors-to-address-the-burden-of-disease/54437/On-demand webcast on the role of interleukin (IL)-13 in atopic dermatitis pathophysiology and strategies for leveraging IL-13 inhibitors to address disease burden and improve patient outcomes.Red Blood Cell Alloimmunization, Pathophysiology, Diagnosis, Treatment, and Prevention
https://reachmd.com/programs/cme/red-blood-cell-alloimmunization-pathophysiology-diagnosis-treatment-and-prevention/13907/HDFN is rare, under recognized, and undermanaged. Are you doing everything you can to mitigate potentially devastating outcomes for your patients?Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma
https://reachmd.com/programs/cme/innovations-in-oncology-learning-center-from-guidelines-to-practice-melanoma/33212/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Back to the Future: a History of ACOG in Social Media's Golden Age
https://reachmd.com/programs/clinicians-roundtable/back-to-the-future-a-history-of-acog-in-social-medias-golden-age/7523/From mapping AEDs on a phone app to communicating with colleagues on Facebook, technology has become an integral part of daily life. Some would even call their phones an extension of the human nervous system, as evinced by a near-constant awareness of their battery life. Yet despite this high prevalAddressing Tuberculosis and Multi-Drug Resistance at a Cellular Level
https://reachmd.com/programs/clinicians-roundtable/addressing-tuberculosis-and-multi-drug-resistance-at-a-cellular-level/4132/Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) has been present in the human population since antiquity. Today over 2 billion people have been exposed. What can we learn form this remarkably resilient bacteria, and how do we address the formidable challenge of treating drug r